1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Anti-CD20 Monoclonal Antibodies (mABs) Market: About this market
The anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. The analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, the global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.
Global Anti-CD20 Monoclonal Antibodies (mABs) Market: Overview
High target affinity and specificity of anti-CD20 mABs
Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.
Development of CD20 bispecific antibodies
The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.
Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. The analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, the global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.
Global Anti-CD20 Monoclonal Antibodies (mABs) Market: Overview
High target affinity and specificity of anti-CD20 mABs
Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.
Development of CD20 bispecific antibodies
The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.
Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
The following companies are recognised as the key players in the global anti-CD20 monoclonal antibodies (mABs) market: Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of CD20 bispecific antibodies.”
According to the report, one of the major drivers for this market is high target affinity and specificity of anti-CD20 mABs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of anti-CD20 mABs
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of CD20 bispecific antibodies.”
According to the report, one of the major drivers for this market is high target affinity and specificity of anti-CD20 mABs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of anti-CD20 mABs
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
